

APPLICATIONS

LC/MS/MS Analysis of Immunosuppressants from Whole Blood using Aeris[™] WIDEPORE XB-C18 Core-Shell HPLC/UHPLC Columns

S. Sadjadi, S. Huq, and J. Layne
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

Cyclosporine A, tacrolimus, sirolimus, and everolimus are four of the most commonly administered immunosuppressant drugs and play a central role in the success of tissue and organ transplants. These drugs are most typically analyzed from whole blood using LC/MS/MS. However, because of the analytical challenges posed when working with whole blood, many of the published methods rely upon complex and/or expensive extraction steps utilizing offline solid phase extraction, on-line solid phase extraction, or the use of pre-columns prior to the actual analytical column. In this current work, we present a rapid and effective method for the analysis of these four immunosuppressants from whole blood that use a simple protein precipitation step followed by direct injection onto a wide-pore core-shell HPLC column (Aeris WIDEPORE 3.6µm XB-C18). The method displays excellent accuracy and is sensitive down to the low µg/L (ng/mL) range.

Introduction

Immunosuppressants are a class of drugs that inhibit the body's immune response and are typically administered to prevent the rejection of transplanted organs (e.g. kidney) or tissue (e.g. bone marrow), and may also be used to treat various autoimmune disorders such as Crohn's Disease or rheumatoid arthritis. The first effective immunosuppressant drug was cyclosporine A (or CsA), an undecapeptide, initially discovered by researchers at the pharmaceutical company Sandoz.¹ Since the development of CsA, many other immunosuppressant drugs have been developed, including the macrolides tacrolimus (FK506), sirolimus (also known as rapamycin), and everolimus.

While all of these drugs ultimately act to suppress the immune response, they each exert their effects through different mechanisms. Cyclosporine A binds to the protein cyclophilin, and the resulting CsA-cyclophilin complex blocks the calcineurin-mediated transcription of the interleukin 2 (IL-2) gene in antigen activated T cells, thus preventing the growth, differentiation, and proliferation of T cells that mediate the immune response.^{2,3} Tacrolimus binds to the protein FKBP12 (FK506 binding protein), and the resulting complex prevents the cascade of reactions that ultimately lead to a reduction in IL-2 transcription.³ Unlike CsA and tacrolimus, which block synthesis of IL-2, sirolimus and everolimus exert their activity by blocking the response of T-cells to IL-2.⁴

Liquid chromatography coupled to tandem mass spectrometry (LC/MS/MS) has become the analytical method of choice for the analysis of immunosuppressants. These drugs must be monitored from whole blood, which poses a sample preparation challenge as matrix effects can confound analyses through ion suppression and/or enhancement, and can also affect the reproducibility and accuracy of analytical methods. To overcome the challenges posed when working with whole blood, many methods that have been developed for immunosuppressant analysis involve off-line solid-phase extraction⁵, which can be timeconsuming and expensive, or complex on-line extraction methods that not all labs are equipped to operate.^{6, 7, 8} Herein, we present a simple and rapid method for the analysis of immunosuppressants from whole blood that utilizes a simple protein precipita-

tion step followed directly by LC/MS/MS analysis using a wide-pore coreshell HPLC column. This fast, simple method shows excellent precision and accuracy down to the µg/L concentration range.

Materials and Methods

Reagents

The whole blood used in this study was obtained from Bioreclamation LLC (Westbury, NY). Methanol (LC/MS grade) was purchased from J. T. Baker (Center Valley, PA). Deionized water was used for buffers and sample dilutions. Tacrolimus, everolimus, sirolimus, and cyclosporine A were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). The internal standard used for CsA was cyclosporine D (Cerilliant), and the internal standard for the other immunosuppressants was ascomycin (Cerilliant, Round Rock, TX). Unless stated otherwise, all other reagents used in this study were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA).

Whole Blood Protein Precipitation

To perform the protein precipitation, 0.2 mL whole blood (spiked with analytes and internal standards) was placed into a 1.5 mL polypropylene microfuge tube. 400 µL of methanol/ 2 % zinc sulfate (80:20) dissolved in water was added to the whole blood sample. This mixture was then vortexed vigorously for 10-20 seconds and then centrifuged at 14,000 rpm for 10 minutes at room temperature. The supernatant (~0.5 mL) was transferred to a new autosampler vial, and then directly injected into the LC/MS/MS with a 20 µL injection volume.

Optional: Solid Phase Extraction (SPE)

In this publication, we present a simple method that uses protein precipitation and LC/MS/MS to analyze these immunosuppressants. For users with LC/MS/MS systems that are not as sensitive as the API 5000[™] (AB SCIEX, Framingham, MA) used in the current study, or for researchers or analysts seeking much lower levels of detection and quantitation, we also include an off-line solid phase extraction method of cyclosporine A from whole blood. Using a vacuum manifold, a 30 mg/3 mL Strata[®]-X-CW (weak cation-exchange) solid phase extraction cartridge (Phenomenex, Torrance, CA.) was conditioned with 1 mL of 100 % methanol, followed by 1 mL of 25 mM ammonium bicarbonate (pH 8.3). The protein precipitated whole blood sample was loaded onto the SPE bed and drawn through the SPE cartridge at a slow flow rate (~1 mL/min). The cartridge was then washed with 0.4 mL of the 25 mM ammonium bicarbonate, followed by a second wash using 0.4 mL of methanol/ water (50:50). Under high vacuum, the SPE bed was dried for 4-5 minutes, and then the analytes were eluted from the cartridge using 200 µL of 100 % methanol. This elution step was repeated, and the resulting extracts were combined (400 µL) and evaporated to dryness under a gentle stream of nitrogen at 40-45 °C. The extract residue was re-suspended with 400 µL of methanol/5 mM ammonium formate (pH 3.2) (35:65) and transferred to a glass autosampler vial for LC/MS/MS analysis.



LC/MS/MS Analysis

Analysis was performed using an API 5000TM mass spectrometer (AB SCIEX, Framingham, MA.) coupled to an Agilent[®] 1260 UHPLC system (Agilent Technologies; Santa Clara, CA.). The analytical column was an AerisTM WIDEPORE 3.6 μ m XB-C18 column (50 mm x 2.1 mm), with a SecurityGuardTM ULTRA guard cartridge (both from Phenomenex, Torrance, CA.). Mobile phase A consisted of 5 mM ammonium formate (no pH adjustment) dissolved in deionized water, and mobile phase B consisted of 5 mM ammonium formate dissolved in methanol. The analysis was performed using a simple, rapid gradient going from 35 % B to 95 % B over 1 minute, holding at 95 % B for 1 minute, and then re-equilibrating at the initial 35 % B for 2 minutes between injections. The flow rate was 700 μ L per minute, and the column was maintained at 75 °C.

Multiple reaction monitoring (MRM) of the immunosuppressants was performed using electrospray in positive ion mode. The source was operated at 400 °C with an electrospray voltage of 4000. Ion source parameters were as follows: curtain gas 25, GS1 60, GS2 45, CAD gas. MRM transitions for the analytes are shown in **Table 1**.

Table 1.
MRM transitions for the immunosuppressants and the internal standards

Analyte Name	Q1, Da	Q3, Da
Ascomycin 1	809.6	756.7
Ascomycin 2	809.6	564.5
Everolimus 1	975.8	908.6
Everolimus 2	975.8	926.6
Sirolimus 1	931.6	864.6
Sirolimus 2	931.6	882.8
Tacrolimus 1	821.7	786.4
Tacrolimus 2	821.7	768.5
Cyclosporin A 1	1220.1	1202.9
Cyclosporin A 2	1220.1	425.1
Cyclosporin D 1	1233.9	1216.9
Cyclosporin D 2	1233.9	1198.7

Results and Discussion

Chromatography

Figure 1 contains representative extracted ion chromatograms (XIC) for the MRMs of the selected immunosuppressants and the two internal standards obtained from a spiked, protein precipitated whole blood sample (50 ng/mL for everolimus, sirolimus, tacrolimus; 500 ng/mL for cyclosporine A). Flow before 0.8 minutes and after 2.5 minutes was diverted to waste. All of the immunosuppressants display excellent chromatography, and are eluted in a cycle time of 4 minutes. The total elution window for the immunosuppressants is less than 1 minute, allowing for extremely high sample-throughput for analysts that utilize multiplexing technology. Comparison with the protein precipitated matrix blank (**Figure 2**) shows little or no matrix interference for each of the MRM transitions monitored. Signal-to-noise ratio for each of the analytes at the lowest levels monitored were: CsA 140:1 (25 μ g/L), tacrolimus 23:1 (2.5 μ g/L), sirolimus 34:1 (2.5 μ g/L), evero-

limus 13:1 (2.5 μ g/L). Given the relatively high signal-to-noise ratios, it is clear that, if necessary, it would most likely be possible to accurately identify and quantify the target immunosuppressants at significantly lower levels than were used in the present study.

Quantitation

Absolute recovery values (compared to a pure neat standard) ranged from 73 % for serolimus to 103 % for tacrolimus, with RSD % values for four replicates ranging between 1.3 % and 8.8 % (**Table 2**). Precision and accuracy values are given in **Table 3** for high and low concentration QC samples. Accuracy values ranged from 85.4 % to 114 %, with precision (or imprecision) values of 6.00 % or lower.

Table 2.
Absolute percent recovery of the immunosuppressants from precipitated whole blood

Analyte Name	Conc. (μ g/L)	% Recovery	% RSD (N=4)
Cyclosporine A	500	91.0	6.40
Everolimus	50	77.0	8.80
Serolimus	50	73.0	1.30
Tacrolimus	50	103.0	3.20

Table 3.
Precision and accuracy data for QC samples

Analyte Name	Conc. (μ g/L)	% CV	% Accuracy
Cyclosporine A	150	5.40	113.8
	750	4.30	114.4
Tacrolimus	15	4.40	95.8
	75	4.50	98.3
Sirolimus	15	2.90	100.1
	75	2.70	85.5
Everolimus	15	0.90	108.5
	75	3.80	95.7




Figure 1. Representative extracted ion chromatograms (XIC) of spiked whole blood extract (50 µg/L for Everolimus, Sirolimus, Tacrolimus; 500 µg/L for Cyclosporin A)

App ID 22098




Figure 2. Representative extracted ion chromatograms (XIC) for the protein precipitated whole blood matrix blank

App ID 22098

Conclusions

In this work, we present a simple and effective method for the analysis of four commonly used immunosuppressants obtained from whole blood samples. Using a simple protein precipitation step, we were able to achieve a quantitation of 25 µg/L for CsA, 2.5 µg/L for tacrolimus, 2.5 µg/L for sirolimus, and 2.5 µg/L for everolimus. Signal-to-noise ratios at the lowest level analyzed using this method were greater than 13, indicating that the method is most likely applicable to even lower levels of detection and quantitation. The use of a unique wide-pore core-shell column (Aeris[™] WIDEPOR[™] 3.6 µm XB-C18) provided excellent chromatography for these relatively high molecular weight molecules, and also possesses a surface chemistry that is stable at the elevated temperature used in this assay (75 °C).

References

1. Svarstad, HC Bugge, and SS Dhillon. 2000. Biodiversity and Conservation **9** (11): 1521–1541.
2. S. Matsuda and S. Koyasu. 2000. Immunopharmacology **47**: 119–125.
3. Liu J, Farmer J, Lane W, Friedman J, Weissman I, Schreiber S (1991). Cell **66** (4): 807–15.
4. SN Seghal. 2003. Transplant Proc. **35**(3): 7S–14S.
5. Karapirli M, Kizilgun M, Yesilyurt O, Gul H, Kunak ZI, Akgul EO, Macit E, Cayci T, Gulcan Kurt Y, Aydin I, Yaren H, Seyrek M, Cakir E, Yaman H. ScientificWorldJournal. 2012;2012:571201.
6. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, Kirchner GL. J Chromatogr B Biomed Sci Appl. 2000 Oct 1;748(1):41–53.
7. Deters M, Kirchner G, Resch K, Kaever V. Clin Chem Lab Med. 2002 Mar;40(3):285–92.
8. Buchwald A, Winkler K, Epting T. BMC Clin Pharmacol. 2012 Jan 11;12:2. doi: 10.1186/1472-6904-12-2.



APPLICATIONS

Ordering Information

Aeris™ WIDEPORE 3.6µm Minibore Columns (mm)					SecurityGuard™ ULTRA Cartridges*
Phases	50 x 2.1	100 x 2.1	150 x 2.1	250 x 2.1	3/pk
XB-C18	00B-4482-AN	00D-4482-AN	00F-4482-AN	00G-4482-AN	AJ0-8783
XB-C8	00B-4481-AN	00D-4481-AN	00F-4481-AN	00G-4481-AN	AJ0-8785
C4	00B-4486-AN	00D-4486-AN	00F-4486-AN	00G-4486-AN	AJ0-8899


for 2.1 mm ID

Aeris WIDEPORE 3.6µm Analytical Columns (mm)				SecurityGuard™ ULTRA Cartridges*
Phases	100 x 4.6	150 x 4.6	250 x 4.6	3/pk
XB-C18	00D-4482-E0	00F-4482-E0	00G-4482-E0	AJ0-8769
XB-C8	00D-4481-E0	00F-4481-E0	00G-4481-E0	AJ0-8771
C4	00D-4486-E0	00F-4486-E0	00G-4486-E0	AJ0-8901


for 4.6 mm ID

*SecurityGuard ULTRA Cartridges require holder, Part No.: AJ0-9000


Strata®-X-CW

Format	Sorbent Mass	Part Number	Unit
Tube			
	30 mg	8B-S035-TAK**	1 mL (100/box)
	30 mg	8B-S035-TBJ	3 mL (50/box)
	60 mg	8B-S035-UBJ**	3 mL (50/box)
	100 mg	8B-S035-ECH	6 mL (30/box)
	200 mg	8B-S035-FBJ	3 mL (50/box)
	200 mg	8B-S035-FCH	6 mL (30/box)
	500 mg	8B-S035-HBJ	3 mL (50/box)
	500 mg	8B-S035-HCH	6 mL (30/box)

Giga™ Tube

	1 g	8B-S035-JDG	12 mL (20/box)
	1 g	8B-S035-JEG	20 mL (20/box)
	2 g	8B-S035-KEG	20 mL (20/box)
	5 g	8B-S035-LFF	60 mL (16/box)

96-Well Plate

	10 mg	8E-S035-AGB	2 Plates/Box
	30 mg	8E-S035-TGB	2 Plates/Box
	60 mg	8E-S035-UGB	2 Plates/Box

**Tab-less tubes available. Contact Phenomenex for details.



If Phenomenex products in this technical note do not provide at least an equivalent separation as compared to other products of the same phase and dimensions, return the product with comparative data within 45 days for a FULL REFUND.

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at <http://www.phenomenex.com/TermsAndConditions>.

Trademarks

Strata is a registered trademark, Aeris, Giga, and SecurityGuard are trademarks of Phenomenex. API 5000 is a trademark of AB SCIEX Pte. Ltd. Agilent is a registered trademark of Agilent Technologies, Inc.

Strata-X is patented by Phenomenex. U.S. Patent No. 7,119,145

© 2016 Phenomenex, Inc. All rights reserved.

Australia

t: +61 (0)2-9428-6444
f: +61 (0)2-9428-6445
auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
f: +43 (0)1-319-1300
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
f: +31 (0)30-2383749
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
f: +1 (310) 328-7768
info@phenomenex.com

China

t: +86 (0)20 2282-6668
f: +86 (0)20 2809-8130
chinainfo@phenomenex.com

Denmark

t: +45 4824 8048
f: +45 4810 6265
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
f: +45 4810 6265
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
f: +33 (0)1 30 09 21 11
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
f: +49 (0)6021-58830-11
anfrage@phenomenex.com

India

t: +91 (0)40-3012 2400
f: +91 (0)40-3012 2411
indiainfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
f: +44 1625-501796
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
f: +39 051 6327555
italiainfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
f: +31 (0)30-2383749
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
f: 001-310-328-7768
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
f: +31 (0)30-2383749
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
f: +64 (0)9-4780952
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
f: +45 4810 6265
nordicinfo@phenomenex.com

Puerto Rico

t: +1 (800) 541-HPLC
f: +1 (310) 328-7768
info@phenomenex.com

Spain

t: +34 91-413-8613
f: +34 91-413-2290
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
f: +45 4810 6265
nordicinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
f: +44 (0)1625-501796
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
f: +1 (310) 328-7768
info@phenomenex.com

All other countries Corporate Office USA

t: +1 (310) 212-0555
f: +1 (310) 328-7768
info@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at international@phenomenex.com